684 related articles for article (PubMed ID: 32042320)
1. Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts.
Coussy F; Lavigne M; de Koning L; Botty RE; Nemati F; Naguez A; Bataillon G; Ouine B; Dahmani A; Montaudon E; Painsec P; Chateau-Joubert S; Laetitia F; Larcher T; Vacher S; Chemlali W; Briaux A; Melaabi S; Salomon AV; Guinebretiere JM; Bieche I; Marangoni E
Theranostics; 2020; 10(4):1531-1543. PubMed ID: 32042320
[TBL] [Abstract][Full Text] [Related]
2. PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors.
Lehmann BD; Bauer JA; Schafer JM; Pendleton CS; Tang L; Johnson KC; Chen X; Balko JM; Gómez H; Arteaga CL; Mills GB; Sanders ME; Pietenpol JA
Breast Cancer Res; 2014 Aug; 16(4):406. PubMed ID: 25103565
[TBL] [Abstract][Full Text] [Related]
3. Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers.
Coussy F; El Botty R; Lavigne M; Gu C; Fuhrmann L; Briaux A; de Koning L; Dahmani A; Montaudon E; Morisset L; Huguet L; Sourd L; Painsec P; Chateau-Joubert S; Larcher T; Vacher S; Melaabi S; Salomon AV; Marangoni E; Bieche I
J Hematol Oncol; 2020 Feb; 13(1):13. PubMed ID: 32087759
[TBL] [Abstract][Full Text] [Related]
4. Targeting mTOR pathway inhibits tumor growth in different molecular subtypes of triple-negative breast cancers.
Hatem R; El Botty R; Chateau-Joubert S; Servely JL; Labiod D; de Plater L; Assayag F; Coussy F; Callens C; Vacher S; Reyal F; Cosulich S; Diéras V; Bièche I; Marangoni E
Oncotarget; 2016 Jul; 7(30):48206-48219. PubMed ID: 27374081
[TBL] [Abstract][Full Text] [Related]
5. In vitro effect of PIK3CA/mTOR inhibition in triple-negative breast cancer subtype cell lines.
Kumar S; Bhattacharyya S; Das A; Singh G; Bal A
Breast Dis; 2022; 41(1):241-247. PubMed ID: 35431224
[TBL] [Abstract][Full Text] [Related]
6. Functional characterization of androgen receptor in two patient-derived xenograft models of triple negative breast cancer.
Wang X; Petrossian K; Huang MJ; Saeki K; Kanaya N; Chang G; Somlo G; Chen S
J Steroid Biochem Mol Biol; 2021 Feb; 206():105791. PubMed ID: 33271252
[TBL] [Abstract][Full Text] [Related]
7. Multiple molecular subtypes of triple-negative breast cancer critically rely on androgen receptor and respond to enzalutamide in vivo.
Barton VN; D'Amato NC; Gordon MA; Lind HT; Spoelstra NS; Babbs BL; Heinz RE; Elias A; Jedlicka P; Jacobsen BM; Richer JK
Mol Cancer Ther; 2015 Mar; 14(3):769-78. PubMed ID: 25713333
[TBL] [Abstract][Full Text] [Related]
8. Estrogen receptor beta increases sensitivity to enzalutamide in androgen receptor-positive triple-negative breast cancer.
Anestis A; Sarantis P; Theocharis S; Zoi I; Tryfonopoulos D; Korogiannos A; Koumarianou A; Xingi E; Thomaidou D; Kontos M; Papavassiliou AG; Karamouzis MV
J Cancer Res Clin Oncol; 2019 May; 145(5):1221-1233. PubMed ID: 30805773
[TBL] [Abstract][Full Text] [Related]
9. Molecular Analysis of Luminal Androgen Receptor Reveals Activated Pathways and Potential Therapeutic Targets in Breast Cancer.
Stella S; Vitale SR; Massimino M; Motta G; Longhitano C; Lanzafame K; Martorana F; Fazzari C; Vecchio GM; Tirrò E; Inzerilli N; Carciotto R; Manzella L; Caruso M; Vigneri P
Cancer Genomics Proteomics; 2022; 19(4):464-476. PubMed ID: 35732329
[TBL] [Abstract][Full Text] [Related]
10. Selective activity of deguelin identifies therapeutic targets for androgen receptor-positive breast cancer.
Robles AJ; Cai S; Cichewicz RH; Mooberry SL
Breast Cancer Res Treat; 2016 Jun; 157(3):475-88. PubMed ID: 27255535
[TBL] [Abstract][Full Text] [Related]
11. Patient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition.
Zhang H; Cohen AL; Krishnakumar S; Wapnir IL; Veeriah S; Deng G; Coram MA; Piskun CM; Longacre TA; Herrler M; Frimannsson DO; Telli ML; Dirbas FM; Matin AC; Dairkee SH; Larijani B; Glinsky GV; Bild AH; Jeffrey SS
Breast Cancer Res; 2014 Apr; 16(2):R36. PubMed ID: 24708766
[TBL] [Abstract][Full Text] [Related]
12. Synergy between Androgen Receptor Antagonism and Inhibition of mTOR and HER2 in Breast Cancer.
Gordon MA; D'Amato NC; Gu H; Babbs B; Wulfkuhle J; Petricoin EF; Gallagher I; Dong T; Torkko K; Liu B; Elias A; Richer JK
Mol Cancer Ther; 2017 Jul; 16(7):1389-1400. PubMed ID: 28468774
[TBL] [Abstract][Full Text] [Related]
13. TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR
Lehmann BD; Abramson VG; Sanders ME; Mayer EL; Haddad TC; Nanda R; Van Poznak C; Storniolo AM; Nangia JR; Gonzalez-Ericsson PI; Sanchez V; Johnson KN; Abramson RG; Chen SC; Shyr Y; Arteaga CL; Wolff AC; Pietenpol JA;
Clin Cancer Res; 2020 May; 26(9):2111-2123. PubMed ID: 31822498
[TBL] [Abstract][Full Text] [Related]
14. A large collection of integrated genomically characterized patient-derived xenografts highlighting the heterogeneity of triple-negative breast cancer.
Coussy F; de Koning L; Lavigne M; Bernard V; Ouine B; Boulai A; El Botty R; Dahmani A; Montaudon E; Assayag F; Morisset L; Huguet L; Sourd L; Painsec P; Callens C; Chateau-Joubert S; Servely JL; Larcher T; Reyes C; Girard E; Pierron G; Laurent C; Vacher S; Baulande S; Melaabi S; Vincent-Salomon A; Gentien D; Dieras V; Bieche I; Marangoni E
Int J Cancer; 2019 Oct; 145(7):1902-1912. PubMed ID: 30859564
[TBL] [Abstract][Full Text] [Related]
15. Reciprocal feedback inhibition of the androgen receptor and PI3K as a novel therapy for castrate-sensitive and -resistant prostate cancer.
Qi W; Morales C; Cooke LS; Johnson B; Somer B; Mahadevan D
Oncotarget; 2015 Dec; 6(39):41976-87. PubMed ID: 26506516
[TBL] [Abstract][Full Text] [Related]
16. Phospho-kinase profile of triple negative breast cancer and androgen receptor signaling.
Cuenca-López MD; Montero JC; Morales JC; Prat A; Pandiella A; Ocana A
BMC Cancer; 2014 Apr; 14():302. PubMed ID: 24779793
[TBL] [Abstract][Full Text] [Related]
17. Spectrum of PIK3CA/AKT mutations across molecular subtypes of triple-negative breast cancer.
Kumar S; Bal A; Das A; Loriya I; Khare S; Bhattacharya S; Singh G
Breast Cancer Res Treat; 2021 Jun; 187(3):625-633. PubMed ID: 33954864
[TBL] [Abstract][Full Text] [Related]
18. Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review.
Costa RLB; Han HS; Gradishar WJ
Breast Cancer Res Treat; 2018 Jun; 169(3):397-406. PubMed ID: 29417298
[TBL] [Abstract][Full Text] [Related]
19. Single-Cell Dynamics Determines Response to CDK4/6 Inhibition in Triple-Negative Breast Cancer.
Asghar US; Barr AR; Cutts R; Beaney M; Babina I; Sampath D; Giltnane J; Lacap JA; Crocker L; Young A; Pearson A; Herrera-Abreu MT; Bakal C; Turner NC
Clin Cancer Res; 2017 Sep; 23(18):5561-5572. PubMed ID: 28606920
[No Abstract] [Full Text] [Related]
20. Comprehensive Analysis Identifies Variability in PI3K Pathway Alterations in Triple-Negative Breast Cancer Subtypes.
Basho RK; Zhao L; White JB; Huo L; Bassett RL; Mittendorf EA; Thompson A; Litton JK; Ueno N; Arun B; Lim B; Valero V; Tripathy D; Zhang J; Adrada BE; Santiago L; Ravenberg E; Seth S; Yam C; Moulder SL; Damodaran S
JCO Precis Oncol; 2024 Mar; 8():e2300124. PubMed ID: 38484209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
